Mixed Results With Hormonal Strategies for Premenopausal Breast Cancer
(MedPage Today) -- Pairing ovarian function suppression (OFS) with an aromatase inhibitor significantly reduced the risk of premenopausal breast cancer recurrence but did not improve overall survival (OS) versus a tamoxifen strategy, long-term... (Source: MedPage Today OB/GYN)
Source: MedPage Today OB/GYN - December 20, 2022 Category: OBGYN Source Type: news

Risk - Reducing Medications Can Cut Breast Cancer Death Rates
Tamoxifen with annual screening reduced invasive breast cancers and breast cancer deaths by 40 and 57 percent, respectively (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - December 13, 2022 Category: Cancer & Oncology Tags: Gynecology, Internal Medicine, Oncology, Pharmacy, Radiology, Journal, Source Type: news

Tamoxifen Ups Risk of Uterine Disease, Endometrial Cancer Tamoxifen Ups Risk of Uterine Disease, Endometrial Cancer
New research suggests a nearly fourfold increased risk of endometrial cancer among premenopausal women treated with tamoxifen for breast cancer.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 1, 2022 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Risk of Uterine Diseases, Cancers Up With Tamoxifen Treatment
TUESDAY, Nov. 29, 2022 -- Tamoxifen treatment is associated with increased risk of endometrial hyperplasia, polyps, and carcinoma, as well as other uterine cancers, according to a study published online Nov. 28 in JAMA Network Open. Ki-Jin Ryu,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 29, 2022 Category: Pharmaceuticals Source Type: news

Uterine Cancer: What to Know About Symptoms and Treatment
A new study raised alarms about chemical hair straighteners being linked to the disease, but doctors say there are telltale symptoms to watch for. (Source: NYT Health)
Source: NYT Health - October 25, 2022 Category: Consumer Health News Authors: Dani Blum Tags: Women and Girls Uterus Research Hazardous and Toxic Substances Cancer Black People Gynecology and Gynecologists Estrogen Menopause Tamoxifen (Drug) Source Type: news

2 Years of Endocrine Therapy, 2 Decades of Protection From Metastatic Breast Cancer
(MedPage Today) -- Two years of adjuvant endocrine therapy for premenopausal breast cancer protected against metastatic recurrence for 20 years, a new analysis of a randomized trial showed. Premenopausal women who received goserelin, tamoxifen... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - September 1, 2022 Category: Hematology Source Type: news

Large Benefit From Ovarian Function Suppression in Breast Cancer Large Benefit From Ovarian Function Suppression in Breast Cancer
Eight-year follow-up of the ASTRRA trial confirms and extends support for adding 2 years of ovarian function suppression with goserelin to tamoxifen, compared with tamoxifen alone.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 23, 2022 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Easing Tamoxifen, Aromatase Inhibitors ’ Side Effects for Breast Cancer Treatment
Hormone therapy for breast cancer – such as tamoxifen and aromatase inhibitors – can help prevent the cancer from coming back. If you have side effects, these things may help. (Source: WebMD Health)
Source: WebMD Health - June 21, 2022 Category: Consumer Health News Source Type: news

Twenty Years and Counting: Tamoxifen Benefit in Breast Cancer Twenty Years and Counting: Tamoxifen Benefit in Breast Cancer
New data from a 20-year follow-up of patients with ER-positive/HER2-negative breast cancer identifies those who have lasting benefit from tamoxifen.Medscape Medical News (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - May 11, 2022 Category: Pathology Tags: Hematology-Oncology News Source Type: news

Aromatase Inhibitors May Benefit Premenopausal Women With Breast Cancer
For premenopausal women receiving ovarian suppression, risk for breast cancer recurrence reduced with aromatase inhibitor versus tamoxifen (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - February 11, 2022 Category: Cancer & Oncology Tags: Gynecology, Oncology, Pharmacy, Journal, Source Type: news

Aromatase Inhibitors May Benefit Premenopausal Women With Breast Cancer
FRIDAY, Feb. 11, 2022 -- For premenopausal women with estrogen receptor (ER)-positive breast cancer receiving ovarian suppression, use of an aromatase inhibitor rather than tamoxifen is associated with a reduced risk for recurrence, according to... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 11, 2022 Category: Pharmaceuticals Source Type: news

Oncotarget: Phase 1 study of Z-Endoxifen in patients with solid tumors
(Impact Journals LLC) The Oncotarget article provides evidence that antitumor activity and prolonged stable disease are achieved with Z-endoxifen despite prior tamoxifen therapy. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 17, 2021 Category: Cancer & Oncology Source Type: news

Could Tamoxifen Dose Be Slashed Down to 2.5 mg? Could Tamoxifen Dose Be Slashed Down to 2.5 mg?
Adherence to tamoxifen is notoriously low because of troublesome side effects. Could a substantially lower dose be used instead?Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - March 25, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Lower dose of oestrogen receptor modulator seems to reduce risk of breast cancer
(Karolinska Institutet) While the drug tamoxifen reduces the risk of developing breast cancer and prevents recurrence, the side-effects cause many women to discontinue their treatment. A study involving researchers at Karolinska Institutet in Stockholm has now found that a much lower dose than the standard produces a good effect with fewer adverse reactions in women who have yet to enter the menopause. The study, which has been published in theJournal of Clinical Oncology, can play a significant role in the treatment of cancer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 18, 2021 Category: Cancer & Oncology Source Type: news